Clinical trialNCT03507257Active, not recruitingObservational

Longitudinal Early-onset Alzheimer's Disease Study Protocol

SponsorIndiana UniversityEnrollment850Alzheimer DiseaseEarly Onset Alzheimer DiseaseMild Cognitive Impairment

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Liana Apostolova, MD
Indiana University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Fleni
Buenos Aires, Argentina

Netherlands

Amsterdam Umc
Amsterdam, Netherlands

Spain

Hospital de la Santa Creu I Sant Pau
Barcelona, Spain

Sweden

Lund University
Malmö, Sweden

United Kingdom

University College London
London, United Kingdom

United States

Banner Sun Health Research Institute
Sun City, Arizona, United States
University of California, Los Angeles
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of California, San Francisco
San Francisco, California, United States
Georgetown University
Washington D.C., District of Columbia, United States
Mayo Clinic, Jacksonville
Jacksonville, Florida, United States
Wien Center
Miami Beach, Florida, United States
Emory University
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Mayo Clinic, Rochester
Rochester, Minnesota, United States
Washington University, St. Louis
St Louis, Missouri, United States
Columbia University
New York, New York, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Butler Hospital
Providence, Rhode Island, United States
Houston Methodist Hospital
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Florbetaben →FlortaucipirFluorodeoxyglucose

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2018
Primary completion: 1 Jan 2027
Completion: 1 Jan 2027
Last update posted: 29 Jul 2026
Registered enrollment: 850
Registry id: NCT03507257

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.